Excedrin Migraine & Headache Medication Recall [US]

Click to enlarge image

US/Washington: GSK Consumer Healthcare, a Warren, New Jersey establishment, recalls an estimated 433,600 bottles of Excedrin Migraine Caplets, Excedrin Migraine Geltabs, Excedrin Extra Strength Caplets, Excedrin PM Headache Caplets and Excedrin Tension Headache Caplets from the American marketplace due to reported packaging defects and consequential failure to meet US child resistant closure requirements under the US Poison Prevention Packaging Act with resultant risks of child poisoning, overdose, ingestion and GI tract laceration damage, all serious health and safety hazards.

CPSC: http://ht.ly/O4Qd30rqgVO

Direct link: https://www.cpsc.gov/Recalls/2021/GSK-Consumer-Health-Recalls-Five-Excedrin-Brands-Due-to-Failure-to-Meet-Child-Resistant-Packaging-Requirement-Risk-of-Poisoning

Additional information:
US Consumer Product Safety Commission (“CPSC”) reports this recall involves certain bottles of Excedrin Migraine and Headache Medications, as follows: